The solid progess on sales continues and big pharma are watching closely. Combo data due any day, continuing progress on sales,patent and supply strategy falling into place, NCE ( likely June), Anchor approval (early?), continued success in the field as doctors start to get the mesage that this stuff actually works and the viral pick up that will cause. All good news and teh path ahead looks very bright.
My down side appears to be limited as a long and my risks are understood and limited now. The shorts however have a downside running into $20/30 a share. The shorts appear to be getting more and more desparate looking at some of the posts on here....can only be a good sign.
News 
Market Data 
Discover 
